iX Biopharma FY2026 Results Show Strategic Pivot To US Markets

iX Biopharma Swaps Australian Cannabis for a Massive US Defense Pivot

At first glance, the FY2026 financial results for iX Biopharma Ltd present a paradox. Total revenue fell 12% to $6.85 million, yet the company’s strategic position and financial stability have never been more robust. This strength stems from a decisive pivot away from the softening Australian medicinal cannabis market toward a high-stakes, defense-backed future in the United States.

The US Defense Contract is a Massive Catalyst

The primary driver of this transition is a US$40.95 million sole-source contract awarded by the US Department of Defense (DoD). This supports the Phase 3 clinical development of Wafermine, a patented sublingual ketamine wafer for acute pain. The agreement establishes a dual-track regulatory pathway involving full FDA approval via the 505(b)(2) route and an Emergency Use Authorization (EUA) specifically for military deployment on the battlefield.

Securing a “sole-source” contract is a definitive vote of confidence in the proprietary WaferiX and WaferlogiX delivery platforms. This technology is clinically superior to traditional oral dosing because it provides significantly higher bioavailability. By enabling rapid disintegration and direct absorption through the oral mucosa, the wafers bypass the “first-pass effect” of the gut and liver. Preclinical data for the Group’s sublingual semaglutide, for instance, showed up to 20x higher absorption compared to standard oral forms.

“The Group is uniquely positioned to deliver the therapy using its proprietary WaferiX® sublingual drug delivery technology.”

Margin Expansion Over Top Line Growth

While total revenue declined, the underlying profitability indicates a successful high-margin migration. Gross profit rose 19% to 2.43 million**, and US-based revenue surged to **1.98 million, representing a 14-fold increase over the prior year. This shift reflects a more favorable sales mix as the company prioritize its high-margin US pharmaceutical and nutraceutical operations.

As shown, the 4Q26 margin hitting 48% demonstrates the scaling power of the US pivot, which carries materially higher margins than legacy Australian manufacturing services.

The Compounding Pharmacy Shortcut to Monetization

To bypass the traditional FDA “valley of death” for drug development, iX Biopharma is utilizing the US compounding pharmacy channel. This allows for the immediate monetization of approximately 40 novel products without the multi-year delays of clinical trials. The strategy focuses on high-demand sectors like longevity supplements and hormone replacement therapy. In FY2026, the sublingual NAD+ supplement SL-NAD+ and the sildenafil wafer Wafesil accounted for over 90% of new nutraceutical sales.

Strategically, the Group is currently relocating its freeze-drying and packaging equipment from Australia to a Nevada facility. Targeted for completion in Q3 2026, this move onshores manufacturing to mitigate proposed 100% tariffs on pharmaceutical imports. Furthermore, the regulatory environment is shifting in the Group’s favor; the FDA Pharmacy Compounding Advisory Committee recently recommended adding key peptides like BPC-157 and TB-500 to the 503A Bulks List, a move the Group is monitoring closely for its compounding pipeline.

A Balance Sheet Reborn Through Equity Injections

The financial risk profile of the Group has been fundamentally de-risked. In FY2025, the Group held just 0.87 million** in cash. By the end of FY2026, the cash position reached **14.74 million. This “war chest” was built through three successful private placements and the exercise of warrants, injecting $23.1 million in new equity.

Crucially, the cash position has continued to strengthen post-reporting. Between June 30 and July 17, 2026, the Group received an additional 1.5 million** from further warrant exercises. This capital infusion restored net working capital to a positive **8.6 million, effectively resolving previous “going concern” notes and providing the liquidity necessary to fund Phase 3 DoD requirements and broader US expansion.

The Reality Check on Medicinal Cannabis and Macro Pressures

The “bad news” in the results is concentrated in the legacy medicinal cannabis business, which saw a 46% revenue decline (to $3.47 million). However, this was largely a B2B bottleneck rather than an internal operational failure; the decline was driven by third-party manufacturing volumes and delays on the part of Australian customers in securing their own import permits.

On the expense side, General and Administrative (G&A) costs rose, primarily due to $2.08 million in share-based compensation. While the company remains sensitive to inflationary pressures in Australia and geopolitical supply chain risks, the move to localize production in Nevada is specifically designed to hedge against these exact macroeconomic sensitivities.

The Investor Roadmap for 2027

As the Group enters the 2027 financial year, investors should track three high-impact milestones:

• Nevada Facility Commissioning: Scheduled for Q3 2026, this marks the beginning of onshored US manufacturing and a direct-to-consumer (DTC) telehealth launch.
• EUA Submission and Approval: The potential for military deployment of Wafermine provides a revenue catalyst ahead of full commercial FDA approval.
• Ligo Pharma Restructuring: The establishment of a dedicated US vehicle and a potential joint venture with GLD to form an integrated telehealth and compounding group.

By pivoting toward US defense needs and healthspan optimization, iX Biopharma has traded the volatility of the Australian commodity cannabis market for a high-margin, technology-driven platform with a fortified balance sheet.

Related stories: Trade Wars Force Pasture Holdings Strategic FY2026 Pivot